Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 372 participants.

Also called NCT03902691

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 372 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03902691
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03902691. Randomized; double masking; primary purpose treatment. Start 2019-05-15 (actual); primary completion 2021-02-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis
Condition
Chronic Kidney Diseases
Intervention (Drug)
Pegol-Sihematide
Intervention (Drug)
ESPO
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03902691
Content hash
3f86bd24ba005810df8abad23336c37be852e7ab47c83264dad2dc625ca8b4da